Patient Support Programs, Financial Results, and Stock Price Movements - Analyst Notes on Gilead, Forest Laboratories, Thermo Fisher Scientific, HCA Holdings, and Nektar

NEW YORK, March 6, 2014 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts Review released its analysts' notes regarding Gilead Sciences Inc. (NASDAQ: GILD), Forest Laboratories Inc. (NYSE: FRX), Thermo Fisher Scientific, Inc. (NYSE: TMO), HCA Holdings, Inc. (NYSE: HCA), and Nektar Therapeutics (NASDAQ: NKTR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Gilead Sciences Inc. Analyst Notes

On February 26, 2014, Gilead Sciences Inc.'s (Gilead) stock declined 0.17%, ending the day at $83.81. After opening at $84.05, the stock oscillated in a range of $83.31-$84.50, with total volume of 11.90 million shares. Over the previous three trading sessions, shares of Gilead have increased by 1.48% compared to the Nasdaq Composite which gained 0.67% during the same period. The full analyst notes on Gilead Sciences Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03062014/GILD/report.pdf

Forest Laboratories Inc. Analyst Notes

On February 24, 2014, Forest Laboratories Inc. (Forest) announced the launch of STRIDE (Start Treatment, Real-time Information, Disease Education) patient support program that aims to solve all the queries related to chronic obstructive pulmonary disease (COPD) treatment of patients prescribed Tudorza® and Daliresp®. The Company informed that STRIDE program features a dedicated call center staffed by registered nurses who have been trained to answer questions about each product and reimbursement specialists prepared to address inquiries related to insurance coverage and co-pay assistance. Gavin Corcoran, Executive Vice President Global Medicines Development, commented, "The STRIDE patient support program is the first of its kind for Forest and reinforces our commitment to the COPD community. The important information and services provided through the STRIDE program help patients learn more about their prescribed COPD treatment and empower them to have more productive interactions with their healthcare professionals." The full analyst notes on Forest Laboratories Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03062014/FRX/report.pdf  

Thermo Fisher Scientific, Inc. Analyst Notes

On February 26, 2014, Thermo Fisher Scientific, Inc.'s (Thermo Fisher) stock increased by 0.38%, ending the day at $124.28. The stock opened at $123.87 during the session, and then traded in a range of $123.43-$125.18, with total volume of 2.62 million shares. Over the previous three trading sessions, shares of Thermo Fisher Scientific have increased by 0.89%, compared to the Dow Jones Industrial Average which advanced 0.59% during the same period. The full analyst notes on Thermo Fisher Scientific, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03062014/TMO/report.pdf  

HCA Holdings, Inc. Analyst Notes

On February 26, 2014, HCA Holdings, Inc.'s (HCA) stock increased by 1.86%, ending the day at $50.48. After opening at $49.62, the stock vacillated in a range of $49.41-$50.80, with total volume of 1.32 million. Over the previous three trading sessions, shares of HCA have increased by 0.94% compared to the Dow Jones Industrial Average which rose 0.59% during the same period. The full analyst notes on HCA Holdings, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03062014/HCA/report.pdf  

Nektar Therapeutics Analyst Notes

On February 26, 2014, Nektar Therapeutics (Nektar) reported its financial results for Q4 2013 and full year 2013. Revenues of the Company for the quarter increased to $31.1 million, up 47.3% YoY, primarily due to increased product shipments to one of the Company's collaboration partners. Full year 2013 revenues climbed to $148.9 million, representing a growth of 83.4% YoY, which the management attributed to a $25.0 million milestone achieved in September 2013 upon the acceptance of the naloxegol MAA filing in Europe as well as a $10.0 million milestone achieved upon the initiation of Phase 3 studies for Amikacin Inhale in April 2013. Net loss for the quarter narrowed down to $47.7 million, or $0.41 per diluted share, from $52.9 million, or $0.46 per diluted share, in Q4 2012; and the full year 2013 net loss also came down to $162.0 million, or $1.40 per diluted share, from $171.9 million, or $1.50 per diluted share, in full year 2012. Howard W. Robin, President and CEO of Nektar, commented, "2014 has the potential to be a transformative year for Nektar as several of our highly valuable late-stage programs advance toward approval or filing." The full analyst notes on Nektar Therapeutics are available to download free of charge at:

http://www.AnalystsReview.com/03062014/NKTR/report.pdf

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITOR NOTES:

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsReview.com/

SOURCE Analysts Review